Clinical trials: Liver Steatoses
Adolescent Obesity, Hypertension,Essential
Treatment and Handling Severe Obesity-Related Comorbidities in Adolescents Through Exercise
The main objective of this project is to analyze the effect of a tailor-made, one-to-one, exercise program (aiming to treat and handle obesity-related comorbidities in adolescents with severe obesity at high risk of…
- Conditions
- Adolescent Obesity, Hypertension,Essential, Non-Alcoholic Fatty Liver Disease, Dyslipidemias
- Trial name
- THOR-X (NCT06520800)
- Testing
- Treatment and handling obesity-related comorbidities in adolescents through exercise
- Volunteers
- 24 people
- Sponsor
- University of Lisbon
Non-alcoholic Fatty Liver Disease
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
The objective of this study is to provide clinical data to support the effectiveness of a mixture of ingredients of natural origin, suitably selected and packaged, in the protection from liver damage, in subjects with NAFLD.
- Trial name
- NUTRAFAST (NCT02369536)
- Testing
- nutraceutical mixture
- Where
- Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with MASLD, particularly in the setting of compensated…
- Trial name
- S-MASH (NCT07440511)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fatty Liver, Dyslipidemias
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.
- Conditions
- Fatty Liver, Dyslipidemias, Diabetes Mellitus
- Trial name
- NCT01720719
- Testing
- atorvastatin, Vitamin E
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xin Gao
NASH - Nonalcoholic Steatohepatitis
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)
This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.
- Trial name
- ENLIVEN (NCT04929483)
- Testing
- BIO89-100
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 222 people
- Sponsor
- 89bio, Inc.
Ulcerative Colitis, Crohn's Disease
Multimodal Approach in IBD Patients
The investigators intend to assess the role of several biomarkers in the prediction of relapse in IBD. Clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the…
- Conditions
- Ulcerative Colitis, Crohn's Disease, Nonalcoholic Fatty Liver Disease (NAFLD), Vitamin D Deficiency
- Trial name
- MAID (NCT01705522)
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Colentina
NAFLD
Correlation Between Hepatic Fibrosis and Cardiovascular Risk Evaluated by Non-invasive Tests in Patients With NAFLD
This study aims to examine the link between Non-Alcoholic Fatty Liver Disease (NAFLD) and cardiovascular diseases by studying the association between liver fibrosis degree and cardiovascular risk factors.
- Trial name
- Cardio-NASH (NCT04774302)
- Where
- 2 sites in France
- Volunteers
- 292 people
- Sponsor
- Clinique Pasteur
HIV Infections, Hepatic Steatosis
Pioglitazone to Treat Fatty Liver in People With HIV Infection
This study will determine whether pioglitazone (Actos, a drug approved to treat diabetes, can benefit HIV-infected people with fatty liver.
- Conditions
- HIV Infections, Hepatic Steatosis, Insulin Resistance
- Trial name
- NCT00441272
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
NASH - Nonalcoholic Steatohepatitis
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- Trial name
- HM-TRIA-201 (NCT04505436)
- Testing
- HM15211
- Where
- 60 sites in United States, South Korea
- Volunteers
- 215 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Overweight and Obesity
The Metabolic Impact of Intermittent Carbohydrate Restriction in Individuals With Type 2 Diabetes
The primary aim of this randomized cross-over intervention study is to investigate the effect of four weeks of intermittent carbohydrate restriction (alternating between two days of normal dietary intake and two days of…
- Conditions
- Diabetes Mellitus, Type 2, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- INTERCARB (NCT06144593)
- Testing
- Dietary macronutrient composition
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Hvidovre University Hospital
Hepatitis C, Hepatic Steatosis
Oxidative Stress and Fatty Acids in Hepatitis C
Hepatitis C virus infection (HCV) is a major health concern in Canada and worldwide. Chronic HCV can cause progressive liver damage leading to inflammation, scarring and, in some cases, cirrhosis or liver cancer.
- Trial name
- NCT00444002
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Johane Allard
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018
Effects of Probiotic on Inflammation and Microbiota in Patients With NASH
Individuals with clinically identified non-alcoholic fatty liver disease will undergo baseline evaluation of IL-17 and other inflammatory markers as well as microbiome determination.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Probiotics MeSH Descriptor Data 2018, Interleukin-17 MeSH Descriptor Data 2018
- Trial name
- NASHPro (NCT03511365)
- Testing
- Probiotic Formulation VSL#3
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwell Health
Aging, Menopause
Gonadal Hormone, Gonadotropin and Cardiovascular Events
Deficiency in gonadal hormone has been considered to play a role in ageing related increased incidence of cardiovascular events. But the mechanism has not been fully elucidated.
- Trial name
- NCT02810821
- Where
- China
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- Shandong Provincial Hospital
Non-alcoholic Fatty Liver Disease
The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease
The principal purpose of this study is to determine whether increased intakes of n-3 polyunsaturated (omega-3) fatty acids will reduce the amount of fat stored in the liver in patients with non-alcoholic fatty liver disease.
- Trial name
- NCT00819338
- Testing
- Efamax
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- University of Nottingham
Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors
The Development of MASLD Among Survivors of Breast or Colorectal Cancer
A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly.
- Conditions
- Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- EVALUATE (NCT07280143)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Bern
Non-alcoholic Fatty Liver Disease
Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.
The non-alcoholic fatty liver disease (NAFLD) represents the most common cause of liver disease in the western world. It can progress from steatosis to non-alcoholic steatohepatitis (NASH), and then onto cirrhosis where there is…
- Trial name
- NCT01985009
- Testing
- FibroScan® examination.
- Where
- 7 sites in United Kingdom
- Volunteers
- 450 people
- Sponsor
- Echosens
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04389593
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Nonalcoholic Steatohepatitis (NASH)
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT04616014
- Testing
- ORMD-0801 QD
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Oramed, Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.